Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CRB-0401 by China Resources Pharmaceutical Group for Non-Small Cell Lung Cancer: Likelihood of Approval
CRB-0401 is under clinical development by China Resources Pharmaceutical Group and currently in Phase II for Non-Small Cell Lung Cancer....